With each passing year, we gain new insight and understanding around the clinical utilization of lipid-lowering therapeutic agents. Our historical experience with older agents can often inform our knowledge and interpretation of how we view newly available options and those in development. How does our prior experience with statins and LDL-C lowering help us to better utilize and contextualize the newest classes of specialized high-intensity therapies? When do we consider off-label drug use in patient populations without outcomes data? Where is the future of individualized risk management headed? These are the some of the questions our expert presenters addressed with a live audience in Philadelphia. LEARN MORE »
(May 2017)

Past-President of the National Lipid Association and Editor-in-Chief of the Journal of Clinical Lipidology, Dr. W. Virgil Brown is joined by Drs. Yehuda Handelsman, Pamela Morris, and Seth Martin to discuss new issues in lipoprotein management, including assessment of treatment targets, documenting and using new targets of treatment and goals-setting for these lipoprotein targets. This includes the use of clinical trial data and the feasibility of applying new laboratory measures into guidelines for clinical practice. Finally, they discuss the importance of developing new data management and analysis systems to make the summative effect of the laboratory measurements relevant to the individual patient. LEARN MORE »
(Nov. 2016)

This SAP is offered as part of the NLA's Translational Science of the LDL-Receptor Core Curriculum Intensive Program, which provides a comprehensive, in-depth indoctrination to advanced lipid science. The program is designed to address knowledge, competence, and practice gaps in managing residual CVD risk related to high LDL-C, and to provide lipid specialists with improved proficiency on the functionality and clinical implications of the LDL-Receptor and the complexities of LDL metabolism and targets of therapy. LEARN MORE »
(Jan. 2017)